ArticleHemaSphere2026
Iron, arginine, and redox metabolism in peripheral blood mononuclear cells distinguishes sickle cell disease and pulmonary hypertension.
Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Pulmonary hypertension (PH) is a severe vascular complication of sickle cell disease (SCD); yet, not all patients with SCD develop PH, and PH also arises independently. This duality underscores the need to understand their intersecting biology. We integrated metabolomic, proteomic, and elemental analyses of human peripheral blood mononuclear cells (PBMCs) from individuals with SCD, PH, combined SCD-PH, and healthy controls to define shared and distinct mechanisms. PBMCs from SCD patients, regardless of PH status, displayed significantly elevated intracellular iron, consistent with chronic hemolysis and erythrophagocytosis. Multi-omic profiling revealed condition-specific immune-metabolic signatures: SCD PBMCs showed mitochondrial suppression and reduced oxidative phosphorylation; PH PBMCs showed dysregulated arginine and creatine metabolism, implicating nitric oxide and polyamine pathways; and SCD-PH PBMCs displayed amplified hemoglobin/iron handling, oxidative stress, and immune activation. Unsupervised clustering confirmed discrete phenotypes, with greatest overlap between SCD and SCD-PH, reflecting the additive impact of hemolysis-driven iron loading and PH-driven metabolic remodeling. Histological validation of SCD-PH lung tissue demonstrated iron accumulation in perivascular macrophages, supporting a mechanistic link between systemic PBMC remodeling and pulmonary vascular pathology. Together, these findings establish PBMCs as a readily accessible compartment that mirrors disease-specific metabolic and immune alterations. By capturing iron, arginine, and redox pathways across SCD, PH, and SCD-PH, our study positions PBMC profiling as a novel tool for mechanistic insight, patient stratification, and biomarker discovery and novel interventions.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.